Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.

Scientific reports - 9 Dec 2021

Aslam Sara, Ameer Sonia, Shabana N A, Ahmed Mehboob

Abstract excerpt

Chemotherapy related toxicities have been the major factor limiting the success of acute lymphoblastic leukemia (ALL) induction therapy. Several factors, including the pharmacogenetics of asparaginase and anthracyclines, could contribute to difference in treatment outcome in ALL. We investigated the significance of variations in genes involved in hepatic and cardiac toxicity in acute lymphoblastic leukemia (ALL)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Drug-Related Side Effects and Adverse Reactions

Share to Gene Frequency

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Open in PubMed Open full text

Identifiers

PMID: 34887513
DOI: 10.1038/s41598-021-03208-9
PMCID: PMC8660848

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.PMID 34887513Read ↗

Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review)Semantic proximity Read ↗

[Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood].Semantic proximity Read ↗

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.Semantic proximity Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

Polygenic risk score-assessment of drug induced hepatotoxicity in high-risk acute lymphoblastic leukemiaSemantic proximity Read ↗

Evaluation of Methotrexate Toxicity and its Association with ABCB1 Genetic Polymorphism in Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL Study GroupSemantic proximity Read ↗

Gene polymorphisms in childhood ALLSemantic proximity Read ↗

Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.Semantic proximity Read ↗

DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.